CAREERS Careers Overview Life at Lupin Campus Connect Learning & Development Current Openings P.L.E.D.G.E.
CONTACT US Contact Us Global Offices Partner With Us Lupin for Suppliers GST Information

The NDDD team has developed a pipeline of highly differentiated and innovative new chemical entities in focused therapeutic areas of Oncology, Immunology and Metabolic Disorders.

Current Clinical Programs:


The clinical Phase-I study successfully completed in Europe and the product was found to be safe and well tolerated. Phase-II study has been initiated in India in chronic kidney disease patients on dialysis and also not-on-dialysis.


Clinical Phase-I study has been successfully completed in Europe on terminally-ill patients (Lung Cancer, Melanoma & Colon Cancer). Phase-II study has commenced in India for treating a refractory type of Lung cancer which has RAS mutations for which no treatment exists worldwide.

Lupin and Boehringer Ingelheim agreement

In 2019 Lupin and Boehringer Ingelheim announced a licensing, development and commercialization agreement for Lupin’s MEK inhibitor compound (LNP3794) as a potential targeted therapy for patients with difficult-to-treat cancers. The partnership aims to develop Lupin’s lead MEK inhibitor compound in combination with one of Boehringer Ingelheim’s innovative KRAS inhibitors for patients with gastrointestinal and lung cancers harboring a broad range of oncogenic KRAS mutations.